EP64 – Right upper paraesophageal lymph node is a novel predictive factor of locoregional recurrence in right side PTC

     

    Shin, Sung-Chan1; Kwon, Hyun-Keun1; Sung, Eui Suk2; Jeon, Yun Kyung3; Kim, Bo Hyun3; Kim, In Joo3; Lee, Jin-Choon2; Wang, Soo-Geun1; Lee, Byung-Joo1
    1 Department of Otorhinolaryngology Head and Neck Surgery, Pusan National University Hospital, Busan, Korea
    2 Department of Otorhinolaryngology Head and Neck Surgery, Pusan National University Yangsan Hospital, Busan, Korea
    3 Division of Endocrinology and Metabolism, Department of Internal Medicine, Pusan National University Hospital, Busan, Korea

     

    Background: Central lymph node metastasis is associated with prognostic factors for locoregional recurrence. Right upper paraesophageal lymph nodes(UPELNs) are often overlooked during central-compartment lymph node dissection(CLND) for papillary thyroid carcinoma(PTC) patients. Therefore, we investigated the related factors and the prognostic implication of loco-regional recurrence for right UPELN metastasis in right-side PTC.

    Methods: Records from 763 patients with PTC who underwent total thyroidectomy with CLND including right UPELNs were reviewed retrospectively between January 2007 and March 2015.

    Results: 127 of 763 patients with right-side PTC exhibited nodal metastasis in right UPELNs. In univariate analysis, Right UPELN metastasis was significantly associated with gender, tumor size(>10mm), T stage, extrathyroid extension(ETE), lateral neck lymph node metastasis (p<0.05, respectively). In multivariate analysis, central compartment lymph node(CLN) metastasis (OR 5.203, 95% CI 2.864-9.453), lateral neck lymph node (LLN) metastasis (OR 3.668 , 95% CI 2.375-5.667) were independently correlated with right UPELN metastasis. Right CLN metastasis and UPELN metastasis predicted significantly right LLN metastasis (OR 3.777, 10.325, respectively, p<0.001). 23 (3.0%) patient revealed loco-regional recurrence. Comparing the recurrence rate in the group with CLN metastasis and the group with right UPELN metastasis, the recurrence rate was significantly higher in the group with right UPELN metastasis (p<0.001).

    Conclusions: Right CLN metastasis and lateral LN metastasis were significantly independent predictors of right UPELN metastasis. In addition, the loco-regional recurrence rate was significantly higher in the patients with right UPELN metastasis. These results suggested that right UPELN metastasis should be considered as a novel prognostic factor for locoregional recurrence in right-side PTC.

     

    References:

    1. Bae SY, Yang JH, Choi MY, Choe JH, Kim JH, Kim JS. Right paraesophageal lymph node dissection in papillary thyroid carcinoma. Ann Surg Oncol 2012;19:996–1000.
    2. Lee BJ, Lee JC, Wang SG, Kim YK, Kim IJ, Son SM. Metastasis of right upper para-esophageal lymph nodes in central compartment lymph node dissection of papillary thyroid cancer. World J Surg 2009;33:2094–2098.
    3. Kim YS, Park WC. Clinical predictors of right upper paraesophageal lymph node metastasis from papillary thyroid carcinoma. World J Surg Oncol 2012;10:164.
    4. Zhang L, Liu H, Xie Y, Xia Y, Zhang B,Shan G et al. Risk factors and indication for dissection of right paraesophageal lymph node metastasis in papillary thyroid carcinoma EJSO 2016;42: 81-86
    5. Grodski S, Cornford L, Sywak M et al. Routine level VI lymph node dissection for papillary thyroid cancer: surgical technique. Aust N Z J Surg 2007;77:203–208
    6. Ito Y, Fukushima M, Higashiyama T, et al. Incidence and predictors of right paraesophageal lymph node metastasis of N0 papillary thyroid carcinoma located in the right lobe. Endocr J 2013;60:389–392.
    7. White ML, Gauger PG, Doherty GM. Central lymph node dissection in differentiated thyroid cancer. World J Surg 2007;31:895–904
    8. Ito Y, Jikuzono T, Higashiyama T, Asahi S, Tomoda C, Takamura Y, et al. Clinical significance of lymph node metastasis of thyroid papillary carcinoma located in one lobe. World J Surg. 2006;30:1821–8.
    9. Pinyi Z, Bin Z, Bu Jianlong B, Yao L, Weifeng Z. Risk factors and clinical indication of metastasis to lymph nodes posterior to right recurrent laryngeal nerve in papillary thyroid carcinoma: A single-center study in China. Head and Neck 2014;99:2834-43
    10. Ito Y, Tomoda C, Uruno T, et al. Papillary microcarcinoma of the thyroid:how should it be treated? World J Surg 2004;28:1115–21.
    11. Park JP, Roh JL, Lee JH, et al. Risk factors for central neck lymph node metastasis of clinically noninvasive, node-negative papillary thyroid microcarcinoma. Am J Surg 2014;208:412–8.
    12. Mehanna H, Al-Maqbili T, Carter B, et al. Differences in the recurrence and mortality outcomes rates of incidental and nonincidental papillary thyroid microcarcinoma: a systematic review and metaanalysis of 21,329 person-years of follow-up. J Clin Endocrinol Metab 2014;99:2834–43.
    13. Sivanandan R, Soo KC. Pattern of cervical lymph node metastases from papillary carcinoma of the thyroid. Br J Surg 2001;88:1241–1244.
    14. Kupferman ME, Patterson M, Mandel SJ et al. Patterns of lateral neck metastasis in papillary thyroid carcinoma. Arch Otolaryngol Head Neck Surg 2004;130:857–860.
    15. Noguchi S, Yamashita H, Uchino S et al. Papillary microcarcinoma. World J Surg 2008; 32:747–753.
    16. Lee YS, Lim YS, Lee JC, Wang SG, Kim IJ, Lee BJ. Clinical implication of the number of central lymph node metastasis in papillary thyroid carcinoma: Preliminary report. World J Surg 2010 34:2558–2563.
    17. Marchens A, Hauptmann S, Dralle H. Lymph node dissection in the lateral neck for completion in central node-positive papillary thyroid cancer. Surg 2009 ;145:176-81.
    18. Moo TA, Umunna B, Kato M et al. Ipsilateral versus bilateral central neck lymph node dissection in papillary thyroid carcinoma. Ann Surg 2009; 250:403–408.
    19. Arora N, Turbendian HK, Scognamiglio T et al. Extrathyroidal extension is not all equal: Implications of macroscopic versus microscopic extent in papillary thyroid carcinoma. Surgery 2008;144:942–947 (discussion 947–948).
    20. Ortiz S, Rodriguez JM, Soria T et al.  Extrathyroid spread in papillary carcinoma of the thyroid: clinicopathological and prognostic study. Otolaryngol Head Neck Surg 2001;124:261–5.
    21. Noguchi S, Murakami N, Yamashita H et al. Papillary thyroid carcinoma: modified radical neck dissection improves prognosis. Arch Surg 1998; 133:276–280.
    22. Cushing SL, Palme CE, Audet N et al. Prognostic factors in well-differentiated thyroid carcinoma. Laryngoscope 2004;114:2110–2115.
    23. Ito Y, Miyauchi A. Lateral and mediastinal lymph node dissection in differentiated thyroid carcinoma: indications, benefit, and risk. World J Surg 2007;31:905-15.
    24. Wang TS, Cheung M, Farrokhyar F, Roman SA, Sosa JA. A meta-analysis of the effect of prophylactic central compartment neck dissection on locoregional recurrence rate in patients with papillary thyroid cancer. Ann Surg Oncol 2013;20:3477-83.
    25. Kim GM, Park JB, Bae KS, Kang SJ. Analysis of prognostic factors in patients with multiple recurrences of papillary thyroid carcinoma. Surg Oncol 2012;21:185-90.
    26. Park YM, Wang SG, Lee JC, Shin DH, Kim IJ, Son SM et al. Metastatic lymph node status in the central compartment of papillary thyroid carcinoma: A prognostic factor of locoregional recurrence. Head Neck 2016;38;1172-6.
    27. Suh SH, Pak KJ, Seok JW, Kim IJ. Prognostic Value of Extranodal Extension in Thyroid Cancer: A Meta-Analysis. YMJ 2016;57:1324-8.
    28. Randolph GW, Duh QY, Heller KS, LiVolsi VA, Mandel SJ, Steward DL et al. The Prognostic Significance of Nodal Metastases from Papillary Thyroid Carcinoma Can Be Stratified Based on the Size and Number of Metastatic Lymph Nodes, as Well as the Presence of Extranodal Extension. Thyroid 2012;22:1144-52.
    29. Suh YJ, Kwon H, Kim SJ, Choi JY, Lee KE, Park YJ et al. Factors affecting the Locoregional Recurrence of Conventional Papillary Thyroid Carcinoma After Surgery: A Retrospective Analysis of 3381 Patients. Ann Surg Oncol 2015;22:3543-9

 

Leave a Reply

  • Upcoming Events

     

    World Congress on Thyroid Cancer 3.5
    Rome, Italy | 2019

    Steering Committee
    Rocco Bellatone, MD, Co-Chair
    Celestino Lombardi, MD, Co-Chair
    Gregory Randolph, MD
    Bryan McIver, MD
    Jeremy Freeman, MD
    Ian J. Witterick, MD
    Ashok R. Shaha, MD
    Jatin P. Shah, MD

    World Congress on Thyroid Cancer 4.0
    July 29 – August 1, 2021
    Boston, Massachusetts

     

  • WCTC3.5 Steering Committee:

     

    Rocco Bellatone, Co-Chair
    Celestino Lombardi, Co-Chair
    Gregory W. Randolph, MD
    Bryan McIver, MD
    Jeremy Freeman, MD
    Ian J. Witterick, MD
    Ashok R. Shaha, MD
    Jatin P. Shah, MD